{"title":"妊娠期糖尿病患者血浆内脂素浓度降低。","authors":"Te-Fu Chan, Yi-Ling Chen, Chien-Hung Lee, Fan-Hao Chou, Lee-Chen Wu, Shiang-Bin Jong, Eing-Mei Tsai","doi":"10.1016/j.jsgi.2006.04.007","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To test the hypothesis that plasma visfatin concentrations will be lower in women with gestational diabetes mellitus, we evaluated women with gestational diabetes mellitus and healthy pregnant women, and then correlated their plasma visfatin concentrations with body mass index (BMI) and various other parameters.</p><p><strong>Methods: </strong>A total of 40 women were evaluated: 20 women with gestational diabetes mellitus and 20 healthy pregnant women to serve as control subjects. Plasma visfatin concentrations were analyzed using an enzyme-linked immunosorbent assay.</p><p><strong>Results: </strong>Plasma visfatin concentrations were significantly lower in the gestational diabetes mellitus group (9.4 +/- 3.8 ng/mL) than in the healthy control group (12.6 +/- 4.5 ng/mL) (P = .023). A negative correlation was found between plasma visfatin concentrations and maternal age (r = -0.399, P = .011), first trimester body weight (r = -0.350, P = .027), and first trimester BMI (r = -0.336, P = .034). Multiple linear regression analysis revealed that maternal age (P = .017) and gestational diabetes mellitus/no gestational diabetes mellitus (P = .044) were independently related to plasma visfatin concentrations. However, no relationship was found with either gestational age at the time of sampling or first trimester BMI.</p><p><strong>Conclusions: </strong>Our results show that there are decreased concentrations of plasma visfatin in gestational diabetes mellitus subjects and this may indicate that visfatin plays a role in the pathogenesis of gestational diabetes mellitus. However, further experiments are needed to clarify this role.</p>","PeriodicalId":17373,"journal":{"name":"Journal of the Society for Gynecologic Investigation","volume":"13 5","pages":"364-7"},"PeriodicalIF":0.0000,"publicationDate":"2006-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jsgi.2006.04.007","citationCount":"66","resultStr":"{\"title\":\"Decreased plasma visfatin concentrations in women with gestational diabetes mellitus.\",\"authors\":\"Te-Fu Chan, Yi-Ling Chen, Chien-Hung Lee, Fan-Hao Chou, Lee-Chen Wu, Shiang-Bin Jong, Eing-Mei Tsai\",\"doi\":\"10.1016/j.jsgi.2006.04.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To test the hypothesis that plasma visfatin concentrations will be lower in women with gestational diabetes mellitus, we evaluated women with gestational diabetes mellitus and healthy pregnant women, and then correlated their plasma visfatin concentrations with body mass index (BMI) and various other parameters.</p><p><strong>Methods: </strong>A total of 40 women were evaluated: 20 women with gestational diabetes mellitus and 20 healthy pregnant women to serve as control subjects. Plasma visfatin concentrations were analyzed using an enzyme-linked immunosorbent assay.</p><p><strong>Results: </strong>Plasma visfatin concentrations were significantly lower in the gestational diabetes mellitus group (9.4 +/- 3.8 ng/mL) than in the healthy control group (12.6 +/- 4.5 ng/mL) (P = .023). A negative correlation was found between plasma visfatin concentrations and maternal age (r = -0.399, P = .011), first trimester body weight (r = -0.350, P = .027), and first trimester BMI (r = -0.336, P = .034). Multiple linear regression analysis revealed that maternal age (P = .017) and gestational diabetes mellitus/no gestational diabetes mellitus (P = .044) were independently related to plasma visfatin concentrations. However, no relationship was found with either gestational age at the time of sampling or first trimester BMI.</p><p><strong>Conclusions: </strong>Our results show that there are decreased concentrations of plasma visfatin in gestational diabetes mellitus subjects and this may indicate that visfatin plays a role in the pathogenesis of gestational diabetes mellitus. However, further experiments are needed to clarify this role.</p>\",\"PeriodicalId\":17373,\"journal\":{\"name\":\"Journal of the Society for Gynecologic Investigation\",\"volume\":\"13 5\",\"pages\":\"364-7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2006-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.jsgi.2006.04.007\",\"citationCount\":\"66\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Society for Gynecologic Investigation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jsgi.2006.04.007\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Society for Gynecologic Investigation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.jsgi.2006.04.007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 66
摘要
目的:为了验证妊娠期糖尿病患者血浆内脂素浓度较低的假设,我们对妊娠期糖尿病患者和健康孕妇进行了评估,并将其血浆内脂素浓度与体重指数(BMI)等参数进行了相关性分析。方法:对40例妊娠期糖尿病妇女进行评估,其中20例为妊娠期糖尿病妇女,20例为健康孕妇。采用酶联免疫吸附法分析血浆内脂素浓度。结果:妊娠期糖尿病组血浆内脂素浓度(9.4 +/- 3.8 ng/mL)明显低于健康对照组(12.6 +/- 4.5 ng/mL) (P = 0.023)。血浆内脂素浓度与产妇年龄(r = -0.399, P = 0.011)、孕早期体重(r = -0.350, P = 0.027)、孕早期BMI (r = -0.336, P = 0.034)呈负相关。多元线性回归分析显示,产妇年龄(P = 0.017)和妊娠期糖尿病/无妊娠期糖尿病(P = 0.044)与血浆visfatin浓度独立相关。然而,没有发现与取样时的胎龄或妊娠早期BMI有关。结论:妊娠期糖尿病患者血浆内脂素浓度降低,可能与妊娠期糖尿病的发病机制有关。然而,需要进一步的实验来阐明这一作用。
Decreased plasma visfatin concentrations in women with gestational diabetes mellitus.
Objective: To test the hypothesis that plasma visfatin concentrations will be lower in women with gestational diabetes mellitus, we evaluated women with gestational diabetes mellitus and healthy pregnant women, and then correlated their plasma visfatin concentrations with body mass index (BMI) and various other parameters.
Methods: A total of 40 women were evaluated: 20 women with gestational diabetes mellitus and 20 healthy pregnant women to serve as control subjects. Plasma visfatin concentrations were analyzed using an enzyme-linked immunosorbent assay.
Results: Plasma visfatin concentrations were significantly lower in the gestational diabetes mellitus group (9.4 +/- 3.8 ng/mL) than in the healthy control group (12.6 +/- 4.5 ng/mL) (P = .023). A negative correlation was found between plasma visfatin concentrations and maternal age (r = -0.399, P = .011), first trimester body weight (r = -0.350, P = .027), and first trimester BMI (r = -0.336, P = .034). Multiple linear regression analysis revealed that maternal age (P = .017) and gestational diabetes mellitus/no gestational diabetes mellitus (P = .044) were independently related to plasma visfatin concentrations. However, no relationship was found with either gestational age at the time of sampling or first trimester BMI.
Conclusions: Our results show that there are decreased concentrations of plasma visfatin in gestational diabetes mellitus subjects and this may indicate that visfatin plays a role in the pathogenesis of gestational diabetes mellitus. However, further experiments are needed to clarify this role.